|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS9836 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-Noggin |
| 克隆性 | |
| 靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
| 適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
| 形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
| 宿主 | 詳見(jiàn)說(shuō)明書(shū) |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human Noggin (35-74aa) |
產(chǎn)品訂購(gòu)信息：
英文名稱 Anti-Noggin
中文名稱 指(趾)關(guān)節(jié)粘連NOG蛋白抗體說(shuō)明書(shū)
別 名 NOG; NOGG_HUMAN; Noggin; SYM 1; SYM1; Symphalangism 1 (proximal); Synostoses (multiple) syndrome 1; SYNS 1; SYNS1.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 發(fā)育生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 干細(xì)胞
蛋白分子量 predicted molecular weight: 23kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human Noggin (35-74aa)
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
指(趾)關(guān)節(jié)粘連NOG蛋白抗體說(shuō)明書(shū) 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Noggin is a secreted protein involved at multiple stages of vertebrate embryonic development including neural induction and is known to exert its effects by inhibiting the bone morphogenetic protein (BMP)-signaling pathway. It binds several BMPs with very high (picomolar) affinities, with a marked preference for BMP2 and BMP4 over BMP7. By binding tightly to BMPs, Noggin prevents BMPs from binding their receptors. Noggin binds the bone morphogenetic proteins (BMP) such as BMP-4 and BMP-7, and inhibits BMP signaling by blocking the molecular interfaces of the binding epitopes for both type I and type II receptors. Interaction of BMP and its antagonist Noggin governs various developmental and cellular processes, including embryonic dorsal-ventral axis, induction of neural tissue, formation of joints in the skeletal system and neurogenesis in the adult brain. Noggin plays a key role in neural induction by inhibiting BMP4, along with other TGF-β signaling inhibitors such as chordin and follistatin. Mouse knockout experiments have demonstrated that noggin also plays a crucial role in bone development, joint formation, and neural tube fusion.
Function : Essential for cartilage morphogenesis and joint formation. Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somiteSubunit : Homodimer.Subcellular Location : Secreted.DISEASE : Defects in NOG are a cause of symphalangism proximal syndrome (SYM1) [MIM:185800]. SYM1 is characterized by the hereditary absence of the proximal interphalangeal (PIP) joints (Cushing symphalangism). Severity of PIP joint involvement diminishes towards the radial side. Distal interphalangeal joints are less frequently involved and metacarpophalangeal joints are rarely affected whereas carpal bone malformation and fusion are common. In the lower extremities, tarsal bone coalition is common. Conducive hearing loss is seen and is due to fusion of the stapes to the petrous part of the temporal bone.Defects in NOG are the cause of multiple synostoses syndrome type 1 (SYNS1) [MIM:186500]; also known as synostoses, multiple, with brachydactyly/symphalangism-brachydactyly syndrome. SYNS1 is characterized by tubular-shaped (hemicylindrical) nose with lack of alar flare, otosclerotic deafness, and multiple progressive joint fusions commencing in the hand. The joint fusions are progressive, commencing in the fifth proximal interphalangeal joint in early childhood (or at birth in some individuals) and progressing in an ulnar-to-radial and proximal-to-distal direction. With increasing age, ankylosis of other joints, including the cervical vertebrae, hips, and humeroradial joints, develop.Defects in NOG are the cause of tarsal-carpal coalition syndrome (TCC) [MIM:186570]. TCC is an autosomal dominant disorder characterized by fusion of the carpals, tarsals and phalanges, short first metacarpals causing brachydactyly, and humeroradial fusion. TCC is allelic to SYM1, and different mutations in NOG can result in either TCC or SYM1 in different families.Defects in NOG are a cause of stapes ankylosis with broad thumb and toes (SABTS) [MIM:184460]; also known as Teunissen-Cremers syndrome. SABTS is a congenital autosomal dominant disorder that includes hyperopia, a hemicylindrical nose, broad thumbs, great toes, and other minor skeletal anomalies but lacked carpal and tarsal fusion and symphalangism.Defects in NOG are the cause of brachydactyly type B2 (BDB2) [MIM:611377]. BDB2 is a subtype of brachydactyly characterized by hypoplasia/aplasia of distal phalanges in combination with distal symphalangism, fusion of carpal/tarsal bones, and partial cutaneous syndactyly.Similarity : Belongs to the noggin family.Database links : UniProtKB/Swiss-Prot: Q13253.1
Anti-CK20/FITC 熒光素標(biāo)記細(xì)胞角蛋白20抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Phospho-IRF3 (Ser396)/FITC 熒光素標(biāo)記磷酸化干擾素調(diào)節(jié)因子3抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh CCL20/MIP3 alpha 巨噬細(xì)胞炎性蛋白MIP-3a抗體 規(guī)格 0.1ml
IL-13(Interleukin-13) 白介素13抗原 0.5mg
HSH2D 英文名稱： HSH2D抗體 0.1ml
Rhesus antibody Rh SPA-1/SIPA-1 信號(hào)感應(yīng)增殖相關(guān)蛋白1抗體 規(guī)格 0.1ml
Anti-Phospho-IRF3 (Ser396)/FITC 熒光素標(biāo)記磷酸化干擾素調(diào)節(jié)因子3抗體IgGMulti-class antibodies規(guī)格： 0.2ml
IL-11 ELISA Kit 大鼠白介素11Multi-class antibodies規(guī)格： 48T
Anti-AP2 alpha/FITC 熒光素標(biāo)記轉(zhuǎn)錄激活蛋白2α抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh FAM82A1 微管動(dòng)力調(diào)節(jié)蛋白FAM82A抗體 規(guī)格 0.2ml
MIS/AMH)ELISA Kit 大鼠繆勒管抑制物質(zhì)/抗繆勒管激素 96T
Mitochondrial ribosomal protein L11 英文名稱： 線粒體核糖體蛋白L11抗體 0.2ml
phospho-arfaptin 2 (Ser260) 英文名稱： 磷酸化ADP核糖基化因子結(jié)合蛋白2抗體 0.1ml
Anti-AP2 alpha/FITC 熒光素標(biāo)記轉(zhuǎn)錄激活蛋白2α抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Phospho-GSK-3alpha (Ser21) /FITC 熒光素標(biāo)記兔抗人、大、小鼠等磷酸化葡萄糖合成激酶-3α抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-PAFR/FITC 熒光素標(biāo)記抗血小板活化因子受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Bcl-6/5 原癌基因Bcl-6抗體 規(guī)格 0.2ml
Leptin peptide/FITC 熒光素FITC標(biāo)記瘦素抗原 1mg
GDNF Receptor alpha 2 英文名稱： 膠質(zhì)細(xì)胞系源性神經(jīng)營(yíng)養(yǎng)因子受體α2抗體 0.1ml
Rhesus antibody Rh RAC1+RAC2 GTP結(jié)合蛋白R(shí)AC1+RAC2抗體 規(guī)格 0.2ml
Anti-PAFR/FITC 熒光素標(biāo)記抗血小板活化因子受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
DTMAgar
Elek氏培養(yǎng)基 250(g) incubation media Elek氏培養(yǎng)基 250(g)
萋-尼氏染色液 Ziehl-Neelsen Strain 10毫升×3支 細(xì)菌耐酸染色液
匹克氏肉湯基礎(chǔ)B250用于一次性使用衛(wèi)生用品中溶血性鏈球菌的檢驗(yàn)incubationmedia匹克氏肉湯基礎(chǔ)B250用于一次性使用衛(wèi)生用品中溶血性鏈球菌的檢驗(yàn)
GramStaining
亞碲酸血瓊脂基礎(chǔ)250g用于白喉?xiàng)U菌的分離培養(yǎng)
列文EMB 瓊脂/伊紅亞甲藍(lán)乳糖瓊脂 incubation media 列文EMB 瓊脂/伊紅亞甲藍(lán)乳糖瓊脂
60g/L氯蛋白胨水(PW) 250g 用于副溶血性弧菌增菌培養(yǎng)。(SN 0173-92)
大鼠神經(jīng)干細(xì)胞成星形膠質(zhì)細(xì)胞誘導(dǎo)分化培養(yǎng)基Ratneuralstemcellsintoastrocytesinduceddifferentiationmedium
BrothMedium
指(趾)關(guān)節(jié)粘連NOG蛋白抗體說(shuō)明書(shū) 營(yíng)養(yǎng)肉湯(普通肉湯培養(yǎng)基) 規(guī)格： 250g 用途： 用于一般細(xì)菌培養(yǎng)、復(fù)壯、增菌等，也可用于消毒劑定性消毒效果測(cè)定
麥芽汁培養(yǎng)基 規(guī)格： 250g 用途： 用于酵母菌的增菌培養(yǎng)
麥芽汁瓊脂培養(yǎng)基 規(guī)格： 250g 用途： 供酵母菌的培養(yǎng)、鑒定及保存菌種用。
1%聚山梨酯80-玉米瓊脂培養(yǎng)基 規(guī)格： 100g 用途： 用于白色念珠菌芽管試驗(yàn)的培養(yǎng)
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 指(趾)關(guān)節(jié)粘連NOG蛋白抗體說(shuō)明書(shū) 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）指(趾)關(guān)節(jié)粘連NOG蛋白抗體說(shuō)明書(shū) 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
